eISSN: 1994-4624 / ISSN: 1813-176x
Register
Login
International Journal of Molecular Medicine and Advance Sciences
2006, Volume 2, Issue 3 : 312-318 doi: ijmmas.2006.312.318
Research Article
Increase in Apoptosis by Beta-1 Integrin Blocking Through P21-Dependent and-Independent Mechanisms
Published
June 30, 2005
Abstract

Integrins are the primary receptors used by cells to interact with extracellular matrix. Various  <SUB>1</SUB> and  <SUB>4</SUB> integrin complexes were shown to be involved in the activation of a number of cell cyclin inhibitors.  The  <SUB>4 </SUB>integrin cytoplasmic domain<SUB> </SUB>was shown to be involved in the activation of p21 pathways of growth arrest and apoptosis.  In this study, the  <SUB>1 </SUB>integrin was blocked and cell were cultured on laminin as ECM, thus only the  <SUB>4 </SUB> integrins binds to the ECM.  This way we were able to study the mouse Clara cell cycle progression and death possible through the regulation of p21 in a controlled integrin-ECM binding environment using both wt and p21-/-mice. Upon beta-1 integrin blocking, an increase in apoptosis was observed in Clara cells from both wt and p21 ko mice at 72 and 120 h in culture, the apoptosis rate was higher (p&lt;0.05) in cells from wt mice compared to cells from p21 ko mice at 72 h and  a decrease (p&lt;0.05) in BrdU incorporation was observed in cells from wt mice at 24 and 72 h in culture and in cells from p21 ko mice at 24 h in culture.   Cytoplasmic PCNA expression was found to be higher (p&lt;0.05) in cells from both wt and p21 ko mice upon beta-1 integrin blocking at 120 h and the expression of nuclear PCNA expression significantly increased (p&lt;0.05).  In the absence of p21, there was an increase in cytoplasmic PCNA expression but not nuclear PCNA expression. The expression of PCNA increases in cells from both wt and p21 ko mice but p21 is essential for the nuclear PCNA localisation.

Keywords
License
Copyright (c) International Journal of Molecular Medicine and Advance Sciences
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
Int. J. Mol. Med. Adv. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Recommended Articles
Impact of Climate Change on Human Health
20-26
Clinical Efficacy of Drug-Eluting Stents Among Hypertensive Patients
41-45
Mental Health Awareness and Help-Seeking Behavior: A Comprehensive Study of Knowledge, Attitudes, Barriers, and Interventions
7-12
Healthcare Disparities and Equity in Medical Services: Challenges, Determinants, and Strategies for Achieving Equitable Healthcare
27-34
International Journal of Molecular Medicine and Advance Sciences
+447480266638
+447480266638
support@ijmmas.com
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license. Open Access Publication.
Copyright © ©International Journal of Molecular Medicine and Advance Sciences. All rights reserved.